Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Items 701–800 of 937
Mu, X., Li, H., Zhou, L., & Xu, W. (2019) · Oncology Reports · doi:10.3892/or.2019.7110 · Cited by 16
“When it forms a complex with its partner kinases, including cyclin dependent kinase 4 (CDK4) and CDK6, Cyclin D1, which is overexpressed in a variety of human cancer types, including breast and colon carcinoma cancer (16,54,55), allows cells to proceed into the S phase (56).”
BackgroundCyclins in breast cancer: too much of a good thing
Enders, G. H. (2002) · Breast Cancer Research · doi:10.1186/bcr439 · Cited by 15
“Conversely, germline deletion of cyclin D1 prevents normal proliferation of the breast epithelium during lactation [6,7] and protects against breast neoplasia [8].”
Liu, Y., Lee, C., Lin, C., Chen, H., Liu, G., & Hung, H. (2015) · Oncotarget · doi:10.18632/oncotarget.4469 · Cited by 16
Surprising Dependency for Retinoblastoma Protein in Ras-Mediated Tumorigenesis
DeGregori, J. V. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1165-1169.2006 · Cited by 18
“The rarity of Ras* mutations in the context of Rb gene loss has been proposed previously (14) to relate to low cyclin D1 expression in Rb mutant tumors, together with the demonstrated dependency of Ras*- and Neu-dependent tumorigenesis on cyclin D1 in mice (28, 52).”
BackgroundMatulka, L. A., & Wagner, K. (2005) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2005.05.008 · Cited by 15
Emerging Therapies for Breast Cancer
Goel, S., & Chandarlapaty, S. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041333 · Cited by 17
An evaluation of palbociclib as a breast cancer treatment option: a current update
Gallanis, G. T., Pericas, R. I., Riegel, A. T., & Pohlmann, P. R. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1838485 · Cited by 14
“HER2+ breast cancers have been shown to depend on intracellular signaling via cyclin DCDK4, which lies downstream from the activated HER2 receptor [35,36] (Figure 1).”
BackgroundDominguez-Benot, R., Cimini, A., Barone, D., Giordano, A., & Pentimalli, F. (2022) · Cancers · doi:10.3390/cancers14112709 · Cited by 13
“As a matter of fact, cyclin D1 has strongly exhibited a main role in the development of Her2-driven breast tumors [192].”
BackgroundZhang, Y., Wang, S., & Li, L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2927 · Cited by 13
“The oncogenic activity of cyclin D1 in mammary tissue was demonstrated in mouse models wherein cyclin D1 overexpression led to the development of mammary carcinoma (40), whereas cyclin D1 ablation resulted in mice resistant to cancer induced by several oncogenes (41).”
BackgroundAG36 Inhibits Human Breast Cancer Cells Proliferation by Promotion of Apoptosis In vitro and In vivo
Mu, L.-H., Wang, Y., Wang, D., Zhang, J., Liu, L., Dong, X., Hu, Y., & Liu, P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00015 · Cited by 13
“Cyclin D1 is a critical regulator essential for G1 phase progression and has a causative role in breast cancer formation (Baldin et al., 1993; Yu et al., 2001).”
BackgroundTEKMAL, R. R., Nair, H. B. B., Perla, R. P., & Kirma, N. B. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.05.009 · Cited by 13
“These observations are consistent with previous studies that found mice lacking cyclin D1 are resistant to mammary carcinomas triggered by the ErbB2 oncogene [29].”
Frech, M. S., Torre, K. M., Robinson, G. W., & Furth, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210974 · Cited by 16
“In contrast, cancerous MECs overexpressing ras and neu oncogenes are absolutely dependent on cyclin D1 for malignant transformation (Yu et al., 2001).”
BackgroundThe Tumor Pathology of Genetically Engineered MiceA New Approach to Molecular Pathology
DCARDIFF, R., JMUNN, R., & JGALVEZ, J. (2007) · Elsevier eBooks · doi:10.1016/b978-012369454-6/50052-2 · Cited by 13
Franke, H. R., & Vermes, I. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00293-9 · Cited by 13
Bani, N., Rahmani, F., Shakour, N., Amerizadeh, F., Khalili‐Tanha, G., Khazaei, M., Hassanian, S. M., Kerachian, M. A., Abbaszadegan, M. R., Mojarad, M., et al. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206296355240325113920 · Cited by 13
KiSS1/GPR54 and estrogen-related gene expression profiles in primary breast cancer
Jarząbek, K., Kozłowski, L., Milewski, R., & Wolczynski, S. (2012) · Oncology Letters · doi:10.3892/ol.2012.582 · Cited by 12
O'Sullivan, C. C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1201072 · Cited by 13
“Conversely, knockout of CDK2 or CDK4/6 did not affect cell function or normal development of the mammary gland in this setting (24-27).”
Verma, A. K., Ali, S. A., Singh, P., Kumar, S., & Mohanty, A. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.568660 · Cited by 14
“However, knockout in transgenic mice producing oncogenic protein Ras prevents mammary tumor development (Yu et al., 2001).”
BackgroundRojas, P. A., Benavides, F. J., Blando, J. M., Pérez, C. J., Cardenas, K. T., Richie, E. R., Knudsen, E. S., Johnson, D. G., Senderowicz, A. M., Rodríguez‐Puebla, M. L., et al. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20489 · Cited by 15
“Yet, cyclin D1 null mice are resistant to chemical skin carcinogenesis [11] as well as Ras and Neu transformation in breast cancer models [14].”
BackgroundAge‐related alterations in T‐lymphocytes modulate key pathways in prostate tumorigenesis
Angulo, A. D., Faris, R., Cavazos, D., Jolly, C. A., Daniel, B., & deGraffenried, L. A. (2013) · The Prostate · doi:10.1002/pros.22631 · Cited by 13
“Recent studies suggest that NF-kB-induced cyclin D1 expression is a keycontributing element in mammary breast carcinogenesis [19,20].”
BackgroundLipopeptide adjuvants: monitoring and comparison of P3CSK4- and LPS-induced gene transcription
Müller, M. R., Wiesmüller, K., Jung, G., Loop, T., Humar, M., Pfannes, S. D. C., Bessler, W. G., & Mittenbühler, K. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00030-9 · Cited by 12
Prolactin Promotes Mammary Pathogenesis Independently from Cyclin D1
Asher, J. M., O’Leary, K. A., Rugowski, D. E., Arendt, L. M., & Schuler, L. A. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.041 · Cited by 12
Franke, H. R., Kole, S., Ciftci, Z., Haanen, C., & Vermes, I. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00546-3 · Cited by 12
“It has been demonstrated very recently that mice lacking Cyclin D 1 are resistant to breast cancers induced by the neu and ras oncogenes, both known as acting through the mitogen-activated protein kinase pathway, which is important for the estrogen action in breast cancer cells [20].”
BackgroundImplications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer
Decker, J. T., Ma, J. A., Shea, L. D., & Jeruss, J. S. (2021) · Cancers · doi:10.3390/cancers13215343 · Cited by 13
The LxCxE pRb Interaction Domain of Cyclin D1 Is Dispensable for Murine Development
Landis, M. W., Brown, N. E., Baker, G. L., Shifrin, A., Das, M., Geng, Y., Siciński, P., & Hinds, P. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1207 · Cited by 15
Self-citationRajakumar, T., Pugalendhi, P., & Thilagavathi, S. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00638-9 · Cited by 11
Akhter, N., Alzahrani, F. A., Dar, S. A., Wahid, M., Sattar, R. S. A., Hussain, S., Haque, S., Ansari, S. A., Jawed, A., Mandal, R. K., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28800 · Cited by 11
“CCND1 promotes normal mammary gland as well as mammary tumors development in mice model.(4) In humans too, CCND1 gene is found amplified in up to 20% of breast cancer cases and CCND1 protein overexpressed in more than 50% of mammary tumors.”
BackgroundGhanaatgar‐Kasbi, S., Amerizadeh, F., Rahmani, F., Hassanian, S. M., Khazaei, M., Ferns, G. A., & Avan, A. (2019) · IUBMB Life · doi:10.1002/iub.2136 · Cited by 11
“A large number of malignancies have shown overexpression of cyclin D1 such as breast, bladder, lung, pancreatic, and specifically colorectal cancer.(45,46) Moreover there is growing body of data showing that the association of Cyclin D1 with CRC prognosis.”
BackgroundRetractedRuiz-Miró, M., Colomina, N., Fernández-Hernández, R., Garí, E., Gallego, C., & Aldea, M. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01176.x · Cited by 11
“Although disruption of cyclin D1 is able to restrict mammary and gastrointestinal tumor growth (32,33), overexpression of cyclin D1 is not sufficient for tumorogenesis, and it seems clear that nuclear accumulation of cyclin D1 because of altered nuclear trafficking or degradation also plays an important role in cancer…”
BackgroundCyclin D1 and P27KIP1: The Gatekeepers of Dysplasia
Love, R. M. (2018) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2018/3.1142 · Cited by 12
Cyclin D1 and PSA act as good prognostic and clinicopathological indicators for breast cancer
Holah, N. S., & Hemida, A. S. (2019) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2019.1677706 · Cited by 11
“On the other hand, some studies found that deletion of Cyclin D1 protects against the development of breast carcinoma([24,25]), and that cyclin D1 overexpression is a predictor of poor prognosis.”
BackgroundIn vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches
Simond, A. M., & Muller, W. J. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.004 · Cited by 12
Hamaguchi, T., Matsuoka, Y., Kawaguchi, H., Fukamachi, K., Takasuka, N., Ueda, S., Shimizu, K., Ohki, M., Kusunoki, M., Sakakura, T., et al. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000010698.09512.d2 · Cited by 11
“found that expression of ras and neu/erbB-2 oncogenes leads to exclusive induction of cyclin D1 in mouse mammary epithelial cells, whereas expression of c-myc and Wnt-1 results in induction of both cyclins D1 and D2 [23].”
BackgroundLeung, G., Tsao, S. W., & Wong, Y. C. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1021123914339 · Cited by 11
“It has been reported that cyclin D1-deficient mice were resistant to breast cancers induction by the neu and ras oncogenes [19].”
BackgroundJiao, X., Sante, G. D., Casimiro, M. C., Tantos, Á., Ashton, A. W., Li, Z., Quach, Y., Bhargava, D. K., Rocco, A. D., Pupo, C., et al. (2024) · Oncogenesis · doi:10.1038/s41389-023-00502-1 · Cited by 10
Targeting the cell-cycle machinery for cancer therapy
Peng, Y., Liu, J., Inuzuka, H., Liu, J., & Wei, W. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.08.008 · Cited by 12
The requirement for cyclin E in c-Myc overexpressing breast cancers
Zhou, Y., Geng, Y., Zhang, Y., Zhou, Y., Chu, C., Sharma, S., Fassl, A., Butter, D., & Siciński, P. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1804720 · Cited by 10
Self-citationTargeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance
Gao, X., Wu, Y., Chick, J. M., Abbott, A., Jiang, B., Wang, J., Comte‐Walters, S., Johnson, R. H., Oberholtzer, N. P., Nishimura, M. I., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112314 · Cited by 12
IkB kinase alpha: a link in the chain of the mammary cycle
Clarkson, R. W. E. (2002) · Breast Cancer Research · doi:10.1186/bcr446 · Cited by 11
“Direct regulation of cyclin D1 is, however, a promising proposition, as it is overexpressed in 50% of human primary breast cancers [21].”
BackgroundTargetting Cdks in Cancer: An Overview and New Insights
Chashoo, G. (2014) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000313 · Cited by 11
“Thus, CDK4 inhibition by small molecules may have therapeutic value in treating ErBB2-positive breast tumours [46].”
Background[Effect of starvation-induced autophagy on cell cycle of tumor cells].
Ge, J.-N., Huang, D., Xiao, T., Wang, Z., Li, X., Xiao, H., Tao, D., & Gong, J. (2008) · PubMed · Cited by 10
MMP‐11 promotes papillary thyroid cell proliferation and invasion via the NF‐κB pathway
Zhang, Z., Dong, T., Fu, Y., Zhou, W., Tian, X., Chen, G., & Liu, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27500 · Cited by 10
“Cyclin D1‐deficient mice are resistant to ErbB2‐induced breast cancer and show reduced incidence of skin cancer, suggesting that cyclin D1 plays a role in oncogenesis.(37,38) Moreover, cyclin D1 expression is essential for the maintenance of Erb2‐driven tumors as cyclin D1‐null mice show significantly reduced tumor ce…”
BackgroundSignal Transduction Networks: Ras as a Paradigm
McCormick, F. P. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-313-2_3 · Cited by 11
Dual apoptotic effect of Xrel3 c‐Rel/NF‐κB homolog in human cervical cancer cells
Shehata, M., Shehata, M., Shehata, F., & Pater, A. (2004) · Cell Biology International · doi:10.1016/j.cellbi.2004.09.002 · Cited by 10
“Cyclin D1 is known to be significantly upregulated in cancers (Yu et al., 2001).”
BackgroundCoordinated expression of Rb gene family in the mammary gland
Jiang, Z., & Zacksenhaus, E. (2002) · Mechanisms of Development · doi:10.1016/s0925-4773(03)00089-3 · Cited by 10
The D-Type Cyclins: A Historical Perspective
Sherr, C. J., & Siciński, P. (2017) · Current cancer research · doi:10.1007/978-3-319-64451-6_1 · Cited by 16
Lai, D., Weng, S.-J., Wang, C., Qi, L.-Q., Yu, C., Fu, L., & Chen, W. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.09.040 · Cited by 9
Buongiorno, P., & Bapat, B. V. (2005) · Springer eBooks · doi:10.1007/3-540-27671-8_2 · Cited by 10
“To further highlight the importance of cyclinD1 dysregulation in cancer development, cyclinD1-null mice were shown to be resistant to formation of breast tumors upon stimulation by oncogenic Ras (Yu et al. 2001).”
BackgroundWu, P. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i45.7211 · Cited by 9
Krepinsky, J. C., Wu, D., Ingram, A. J., Scholey, J. W., & Tang, D. (2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.12.1795 · Cited by 13
“Sustained expression of Myc in haematopoietic cells and keratinocytes resulted in the formation of lymphomas and papillomas, whilst inactivation of Myc subsequently led to their regression [101,102].”
BackgroundInfluentialCUEDC2 down-regulation is associated with tumor growth and poor prognosis in lung adenocarcinoma
Sun, L., Bai, L., Lin, G., Wang, R., Liu, Y., Cai, J.-H., Guo, Y., Zhu, Z., & Xie, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3930 · Cited by 9
“Knockdown of cyclin D1 protects mammary tissues from malignant transformation [29].”
BackgroundRetinoid Chemoprevention Trials: Cyclin D1 in the Crosshairs
Freemantle, S. J., Guo, Y., & Dmitrovsky, E. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0218 · Cited by 8
“This finding elegantly shows the key role cyclin D1 plays in carcinogenesis (20).”
BackgroundWang, J. C., Thiere, M., Henne‐Bruns, D., Knippschild, U., & Kornmann, M. (2012) · Pancreas · doi:10.1097/mpa.0b013e3182546de5 · Cited by 8
“For example, mice lacking cyclin D1 or expressing a cyclin D1 mutant that did not activate CDK4 were resistant to breast tumors induced by ErBB2.(33,34) In contrast, lack of cyclin D1 did not affect breast tumor development induced by Myc or Wnt1.”
BackgroundMalumbres, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00004-9 · Cited by 17
Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug- Resistant Cells
Jin, G., Wang, K., Liu, Y., Liu, X., Zhang, X., & Zhang, H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200213102849 · Cited by 9
Identification of cell cycle-targeting microRNAs through genome-wide screens
Hydbring, P., Wang, Y., Bogorad, R. L., Yin, H., Anderson, D. G., Cheng, L., & Siciński, P. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1380132 · Cited by 9
“Analyses of several murine cancer models revealed the requirement for specific cyclins and CDKs both in tumor initiation as well as in tumor maintenance.(8-17) This line of”
BackgroundDisruption of cyclin D1 degradation leads to the development of mantle cell lymphoma
Lu, K., Zhang, M., Qin, H., Shen, S., Song, H., Jiang, H., Zhang, C., Xiao, G., Tong, L., Jiang, Q. Y., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.013 · Cited by 7
“The role of cyclin D1 was further demonstrated by the fact that breast cancer development is delayed when cyclin D1 is deleted in a Neu virus-induced breast cancer animal model 45,46 .”
Cell cycle regulation by bevacizumab in ARPE-19 human retinal pigment epithelial cells
Kuo, C.-N., Chen, C., Lai, C., Lai, L.-J., Wu, P., Hung, C.-H., & Chen, C. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.986 · Cited by 7
Interpretation of Pin-1 and VEGF-C expression in breast infiltrating duct carcinoma
Lim (2009) · Oncology Reports · doi:10.3892/or_00000578 · Cited by 7
Popken-Harris, P. D., Kirchhof, N., Harrison, B., & Harris, L. F. (2006) · Virus Research · doi:10.1016/j.virusres.2006.01.006 · Cited by 7
Weng, A. P., & Aster, J. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00305-2 · Cited by 7
Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer
Glover, C. E., Gurley, K. E., Kim, K.-H., Storer, B. E., Fero, M. L., & Kemp, C. J. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp089 · Cited by 7
Cell proliferation in the normal mouse mammary gland and inhibition by phenylbutyrate.
Kennedy, C. J., Byth, K., Clarke, C. L., & DeFazio, A. (2002) · PubMed · Cited by 9
The Mouse as an Animal Model for Human Diseases
Houdebine, L. (2004) · Elsevier eBooks · doi:10.1016/b978-012336425-8/50059-5 · Cited by 10
Emond, R., Griffiths, J. I., Grolmusz, V. K., Nath, A., Chen, J., Medina, E. F., Sousa, R. S., Adler, F. R., & Bild, A. H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.01.429214 · Cited by 9
“In these tumors, estrogen receptor activity leads to cancer cell proliferation through 72 CDK4/6 activation and cell cycle progression (4-6).”
BackgroundCell cycle proteins: Linking the cell cycle to tumors
Zhong, J., LIU, J., TANG, X., ZHOU, W., Guang-ming, S., ZENG, Y., ZHANG, X., ZHOU, J., Cao, L., Zhang, Q., et al. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.058760 · Cited by 9
Cruz, M. R. D. S., Reinert, T., & Cristofanilli, M. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.965 · Cited by 7
“growth of implanted breast cancer cells (24-27).”
Franco, Y. L., Ramakrishnan, V., Vaidya, T. R., Mody, H. R., Perez, L., & Ait‐Oudhia, S. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09732-x · Cited by 6
Cdk 4/6 inhibitors revolutionized breast cancer therapy
Bandivadekar, P. V., Neve, V., & Patil, P. (2018) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2018.v7.isp6.1.04 · Cited by 6
“Indeed, a wealth of preclinical research has shown that tumor cell proliferation in many breast cancers is underpinned by hyperactivity of the cyclin D–CDK4/6 axis, making pharmacological blockade of this axis an attractive therapeutic strategy ([3-5]).”
Family Cancer Syndromes: Inherited Deficiencies in Systems for the Maintenance of Genomic Integrity
Darbary, H. K., Stoler, D. L., & Anderson, G. R. (2008) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2008.08.001 · Cited by 6
“The degradation of cyclin D also brings about G1 arrest.(60,86)”
BackgroundHorrobin, D. F. (2003) · Medical Hypotheses · doi:10.1016/s0306-9877(03)00075-6 · Cited by 6
Ilyas, M. (2007) · Wiley eBooks · doi:10.1002/9780470025079.chap14.pub2 · Cited by 6
Zhang, Z., Fu, L., Yun, B., Wang, X., Wang, X., Wu, Y., Lv, J., Chen, L., & Wan, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06548-0 · Cited by 6
Promise of Cyclin-Dependent Kinases 4/6 as Therapeutic Targets in Breast Cancer
Yang, C. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000191 · Cited by 5
“In one study, it was demonstrated that ErbB-2 or ras oncogenes failed to induce mammary tumors in cyclin D1 null mice although cyclin D1-deficiency did not hinder tumorigenesis by other oncogenes such as c-myc or Wnt-1 in mice in the same study [8].”
BackgroundMultistage Carcinogenesis: Cell and Animal Models
Kulesz-Martin, M. F., Ouyang, X., Barling, A. N., Gallegos, J. R., Liu, Y., & Medler, T. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.02218-2 · Cited by 5
An insight into the inhibitory selectivity of 4-(Pyrazol- 4-yl)-pyrimidines to CDK4 over CDK2
Dong, K., Yang, X., Zhao, T., & Zhu, X. (2017) · Molecular Simulation · doi:10.1080/08927022.2017.1279283 · Cited by 5
“The above experimental results suggest that people have spent a lot of time and money on the investigation and development of CDK inhibitors, but a few drugs have been put into clinic use [6].”
BackgroundNew Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Verma, P., Mittal, P., Singh, A. K., & Singh, I. K. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666191018172926 · Cited by 5
ZENG, F., Zhou, Y., KHOWTANAPANICH, T., & Saengboonmee, C. (2022) · In Vivo · doi:10.21873/invivo.12868 · Cited by 6
Relevance of Atypical Protein Kinase C Isotypes to the Drug Discovery Process
Jenny, M., Wrulich, O. A., Schwaiger, W., & Ueberall, F. (2005) · ChemBioChem · doi:10.1002/cbic.200400186 · Cited by 7
Molecular Biology of Breast Cancer
Caffarel, M. M., Pensa, S., Wickenden, J. A., & Watson, C. J. (2016) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0023164.pub2 · Cited by 5
Safaroghli‐Azar, A., Mekonnen, L. B., Lenjisa, J. L., Milne, R. W., & Wang, S. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01794-7 · Cited by 5
“Gene-targeted models provided compelling support for this concept: loss of CDK4 or cyclin D1 markedly reduced the incidence of skin and breast tumours, even in the presence of potent oncogenic drivers such as HER2 or Neu-Ras [237–241].”
To, B., Broeker, C. D., Jhan, J.-R., Garcia-Lerena, J., Vusich, J., Rempel, R. E., Rennhack, J. P., Hollern, D. P., Jackson, L., Judah, D., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03172-4 · Cited by 6
Hicks, C., Koganti, T., Brown, A. S., Monico, J., Backus, K. V., & Miele, L. (2013) · Cancer Informatics · doi:10.4137/cin.s11452 · Cited by 4
Wu, Y., Zou, D., Cao, Y., Yao, N., Wang, J., Wang, W., Jiang, H., & Li, G. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1523 · Cited by 4
ChiGuan, L., Bing-wen, H., Huang, C., Yang, H., Cao, L., Huang, J. C., & Hu, C. (2017) · DNA and Cell Biology · doi:10.1089/dna.2016.3562 · Cited by 4
“Cyclin D1 is a key regulator of the G0–G1 transition that occurs during cycling of both normal and cancer cells, and is thought to be a proto-oncogene involved in the initiation and progression of carcinoma (Quelle et al. , 1993; Yu et al. , 2001).”
D-Type Cyclins and Gene Transcription
Sante, G. D., Casimiro, M. C., Li, Z., Ertel, A., Tompa, P., & Pestell, R. G. (2017) · Current cancer research · doi:10.1007/978-3-319-64451-6_3 · Cited by 4
Mammalian Development and Cancer: A Brief History of Mice Lacking D-Type Cyclins or CDK4/CDK6
Kalaszczyńska, I., & Ciemerych, M. A. (2017) · Current cancer research · doi:10.1007/978-3-319-64451-6_2 · Cited by 4
Egr-1 is required for neu/HER2-induced mammary tumors
Oh, S., Kim, H., Nam, K., & Shin, I. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.02.003 · Cited by 4
Malumbres, M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00004-7 · Cited by 6
Yamamoto, T. S., Saito, M., Kumazawa, K., Doi, A., Matsui, A., Takebe, S., Amari, T., Oyama, M., & Semb, K. A. (2011) · InTech eBooks · doi:10.5772/21965 · Cited by 5
“fully sensitive to other oncogenic pathways, such as c-myc or Wnt1 (Yu et al., 2001).”
BackgroundExpression of Cyclin D1 in Tamoxifen Resistant Subline of Human Breast Cancer T47D Cells
Fouladdel, S., Motahari, Z., & Azizi, E. (2004) · International Journal of Cancer Research · doi:10.3923/ijcr.2005.16.20 · Cited by 4
The Utility of Transgenic Mouse Models for Cancer Prevention Research
Hursting, S. D., Lashinger, L. M., Brown, P. H., & Perkins, S. N. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_18 · Cited by 4
The Role of Intrinsic Signaling Pathways in Cell Proliferation
Coleman, H., Abedin, M. R., Powers, K., & Barua, S. (2021) · Nano LIFE · doi:10.1142/s1793984420300034 · Cited by 7
Cell Cycle Control in the Liver
Albrecht, J. H., & Mullany, L. K. (2009) · Wiley eBooks · doi:10.1002/9780470747919.ch62 · Cited by 4
An essential link to mammary cancer?
Geymayer, S., & Doppler, W. (2002) · Nature Medicine · doi:10.1038/nm0202-108 · Cited by 4
The future of therapy for nonseminomatous germ cell tumors
Donadio, A., & Bosl, G. J. (2002) · Chest Surgery Clinics of North America · doi:10.1016/s1052-3359(02)00033-9 · Cited by 4
“Cyclin D1–deficient mice are resistant to the development of breast cancer, supporting the notion that specific protection against breast cancer can be achieved by cyclin D ablation [90].”
BackgroundNovel pharmacological approaches in the treatment of breast cancer
Nahta, R., Hortobágyi, G. N., & Esteva, F. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.6.909 · Cited by 5
“Clinical trials of CCI-779 documented objective responses in patients with refractory breast cancer [108].”
BackgroundBrain, C. T., Chopra, R., Kim, S., Howard, S., & Sung, M. J. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch9 · Cited by 8
PC4: A new regulator of cyclin D1 transcript levels
Fassl, A., & Siciński, P. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202401056 · Cited by 3
CDK4 has the ability to regulate Aurora B and Cenpp expression in mouse keratinocytes
Lee, S., Rodriguez, L. R. L., Majumdar, R., de Marval, P. L. M., & Rodríguez‐Puebla, M. L. (2021) · Oncology Letters · doi:10.3892/ol.2021.12993 · Cited by 3
“Studies demonstrating that inactivation of CDK4 and D‐type cyclins can prevent tumor development in murine models reinforced the view that CDK4 is suitable for cancer‐specific targets (46,47,55,56).”
Background
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.